• Home
  • Content
  • RSS
  • Register
  • Log in

PRforPharma

Discussions about social media, PR and marketing for pharmaceutical companies
  • Home
  • About PRforPharma
  • Resources
  • About Chris Iafolla
  • Want to get a hold of me?

Content Creation: Where Pharma Social Media Goes to Die

July 8th, 2010 by Chris Iafolla View Comments »

Congrats!  You’ve decided to embark on a pharmaceutical social media odyssey.  It will be a rewarding endeavor.  You’ve done everything right up until this point: focused on the Return on Health of the patient, set your pharma social media strategy, outlined a crisis communications plan and hired a pharma social media agency.  You are ready to go.

For the first few weeks everything is humming along like a well-oiled machine.  You engage regularly via Twitter, have quickly cultivated a base of patients on Facebook and have managed to churn out several blog posts.  Everything was going swimmingly as enthusiasm ran high.  But slowly, something changed.  The pace of followers decreased, posts don’t seem to come to life as readily and your Twitter engagement gets pushed to the backburner as that budget meeting looms.

What happened?

Your pharma social media strategy met the fate of many that have gone before it—a lack of content creation.  What started out well-intentioned and maybe even well-planned met its match.  Content creation: where pharma social media goes to die.

Social media programs often start out with the best intentions.  But what many people fail to realize is that social media is difficult.  It takes dedication.  It takes time and it takes internal resources.  It’s not as simple as simple as throwing up a couple of random 140 character thoughts every once in a while.

Content creation is a long slog.  Before you make the commitment to social media, survey the content you already have in house.  If you have a vault of videos that have gone untouched, that might be a good place to start.  Do you have an internal newsletter that might transition well to an external blog?  Think about using that as part of your content creation strategy.  And as rudimentary as it sounds, consider creating an editorial calendar to outline predefined topics for blog posts and assign authors.  This will create some accountability at the outset.  Eventually, you won’t need the calendar as a set of people will become engaged and motivated to post on their own.  But that won’t happen overnight and creating some urgency through a set timeline of posts will keep momentum moving forward.

Content creation is in many respects the linchpin of social media engagement.  It is a wonder then that it often spells the demise of many efforts.

  • Share/Bookmark

View Comments »

Posted in Pharmacetuical Public Relations, Pharmaceutical Social Media, Return on Health

Tags: Pharma social media Pharmaceutical marketing Pharmaceutical PR Pharmaceutical Social Media Return on Health

Failing to Empower the Empowered Patient

July 7th, 2010 by Chris Iafolla View Comments »

A couple of weeks back I had the opportunity to have dinner with a bevy of social media powerhouses including: Marc Monseau of Johnson and Johnson, Laurie Edwards, Jack Barrette from WEGO Health, Shwen Gwee from Vertex Pharmaceuticals, Paul Levy from Beth Israel Deaconess Medical Center, e-Patient Dave deBronkart and Alicia Staley.  As you can see, this was the type of conversation that does not happen frequently enough—a melting pot of patients, pharma people, hospital executives and agency wonks.  The conversation ranged from new babies, to babies on the way, to social media strategy, to the challenges of searching for information on rare diseases.  But what stood out to me the most during the course of the conversation resulted in both satisfaction and frustration.  The Holy Grail for pharma social media remains empowering the patient.

That was a satisfying piece of information in the sense that I’ve long trumpeted the need for social media strategies focused on the Return on Health of the patient.  It’s always nice to affirm that you are not crazy.  It was frustrating because what I heard from the table was it was a need mostly going unmet. What became apparent to me during our dinner was that this is not a problem that can be solved by pharmaceutical companies in isolation.  Just like pharmaceutical social media engagement should not take place in a vacuum, creating a healthcare system where the patient is empowered to play a larger role in the decision-making process requires systems thinking.

Pharmaceutical companies can lead the charge in part because of their unique access to information but also because of their substantial sphere of influence.  Pharmaceutical companies have access to the best information available on treatment options, dealing with side effects and current research.  Like it or not, they also have pull on capital hill, with insurance providers, in the doctor’s office and with the patient.  Pharmaceutical companies must serve as the catalyst to empowering the patient.

But the process can’t stop there.  As agency people, we tend to focus our energies on swaying the folks that write the checks.  In order to truly empower the patient, we need to broaden our field of vision.  How can we expect the empowered patient to achieve a good outcome when doctors are incentivized to see more patients and not spend more time with patients?  What good is an empowered patient if she can’t find information on the latest clinical trials on her rare disease because search algorithms do not lend themselves to uncovering that information?  What’s the use of an empowered patient if doctors are not trained to take input?

I admit I am raising a problem far too complex for me to solve—something that requires brains far smarter than mine.  But I am smart enough to realize that pharmaceutical companies engaging in social media alone will not empower the patient—we need the collaboration of lawmakers, insurance providers, hospitals, doctors and patients.

Even with this complexity, it all centers on the patient.

  • Share/Bookmark

View Comments »

Posted in Pharmacetuical Public Relations, Pharmaceutical Online Marketing, Pharmaceutical Social Media, Return on Health

Tags: Pharma social media Pharmaceutical marketing Pharmaceutical PR Pharmaceutical Social Media PR for pharma Return on Health

Crisis is the Mother of Invention

July 1st, 2010 by Chris Iafolla View Comments »

There is an old adage that necessity is the mother of invention.  Recently amidst the endless stream of Tweets I see, I saw a different take on this saying: “Crisis is the mother of invention.”

(I wish I could remember who Tweeted that so I could give proper recognition, but alas, I can’t.  So to my stranger-Tweeting friend, thank you!)

It struck me as a particularly relevant comment for the world of pharmaceutical social media.  I’ve touched on the fact that pharmaceutical stumbles in social media are a good thing and that it is indeed possible to use social media for pharma crisis communications.  My contention has always been that each challenge along the way illuminates the fact that social media is not some fly-by-night marketing technique.  There are always stumbles in a marketing program, and there will always be challenges, the belief that social media would somehow circumvent that has always hurts its credibility.

As pharmaceutical companies have encountered struggles in social media it has sharpened all of our thinking on the best approach to engagement.  In the early phases of pharma social media—a company was praised simply for showing up.  As well they should have been at the time.  A pharmaceutical company showing its face online was a novel idea three years ago.  During this period, our thinking was never stretched and our approach was never challenged.  It was kind of like elementary school—everyone got a gold star just for trying their best.

No longer.

The recent string of pharmaceutical mishaps has been the crisis that will spur invention.  It will force social media pundits to take a closer look at the thought process behind an engagement and reevaluate the best approach.  More importantly, it will force pharmaceutical companies to ask the right questions before embarking on a social media journey, pinpoint the right goals and insist on outlining a strategy and crisis communications plan.

  • Share/Bookmark

View Comments »

Posted in Pharmacetuical Public Relations, Pharmaceutical Crisis Communications, Pharmaceutical Online Marketing, Pharmaceutical Social Media

Tags: Pharma social media Pharmaceutical Crisis Communications Pharmaceutical Social Media PR for pharma

A Culture of Nitpickers

June 25th, 2010 by Chris Iafolla View Comments »

I recently watched a video on the kitchen-gadget company Oxo.  While you may not expect it at first glance, Oxo is widely regarded as a world-class product design organization.  It’s the kind of company that routinely thinks of ideas of the: “why the heck didn’t I think of that variety?”  The video was on the company’s design philosophy and had a quote that struck me as particularly interesting: “We are a culture of nitpickers; we have to be to get it right.”

The idea behind the nitpicking philosophy is that every product-design decision is put through a firing squad of questioning.  Only if you try to poke holes in your own concept will you ultimately create the best product possible—no detail is too small.  Of course, most people when pressed would say they loathe working with nitpickers.  They slow down the process, obsess over small details and can’t see the big picture are the common complaints.  But in pharmaceutical social media, a healthy does of nitpicking might be just what the doctor ordered.

Let me explain.  Ask a pharmaceutical executive to describe a typical social media person and you will get something that describes a person long on creative juices but short on strategy and project management skills.  This results in an abundance of “big ideas” with little idea of how to implement those ideas or the business drivers that make that a reasonable course of action.  This creates false promises and failed programs.

A culture of nitpickers would approach this process differently.  Once a big idea is pinpointed, the next question is: “does this make sense given the goals we have (presumably) outlined?”  This would be followed by a series of detail-oriented questions that delve into the minutia of a social media engagement.  Should we allow comments?  If so, should they be pre-approved or in real time?  What will the terms of engagement be?  What are grounds for deleting a comment?  How will we handle adverse events or a disgruntled patient?  You get the picture.

Creating a culture of nitpickers is not about stifling innovation—just ask Steve Jobs.  Jobs is the Grand Poobah of nitpicking and few would accuse Apple of a lack of innovation.  It’s about marrying the “big ideas” with the “little details.”  Pharmaceutical social media is too often happening with only big ideas and no concern for the details.  Maybe it’s time we start acting like the company that invented rubber-handled potato peelers and become a culture of nitpickers.

  • Share/Bookmark

View Comments »

Posted in Pharmacetuical Public Relations, Pharmaceutical Online Marketing, Pharmaceutical Social Media

Tags: Pharma social media Pharmaceutical marketing Pharmaceutical PR Pharmaceutical Social Media

Pharmaceutical Companies Among the Least Liked on Facebook

June 23rd, 2010 by Chris Iafolla View Comments »

According to research from Hubspot, pharmaceutical companies are among a group of the least liked industries on Facebook.  Hubspot has evaluated a dataset of 500,000 Facebook groups and come up with an average fan base of 624.  The pharmaceutical portion of that dataset looks to have (the exact number is not provided) an average fan base of 550-575—slightly below average.

These numbers are all well and good but my question is this: should we be judging social media success purely on the ability to amass a large following?

For the record, Hubspot makes no such implications in the post outlining the data, and instead merely presents the empirical data it has found.  But much of the chatter I’ve seen thus far in the dreaded pharma social media echo chamber uses this data to bemoan the lack of success pharmaceutical companies have had on Facebook.  Blindly interpreting data as a benchmark for success is a futile exercise.

For starters, did anyone actually expect the pharmaceutical industry to be higher than average when it comes to the fan base it has accumulated?  We are talking about an industry that is fighting long-held distrust, strict regulations and sensitive topics.  The hill is a bit steeper for healthcare companies than it is for the movie industry (the most liked industry according to a separate post).  Frankly, I’m a bit surprised that the pharma industry is that close to average.

The more important issue at hand is the idea that Facebook fans is an accurate measure of success in social media—particularly pharma social media.  I don’t buy that.  It should be part of the equation but it provides only a small glimpse into the success of your social media strategy.  In the pharmaceutical industry, we should be taking a closer look at the level of engagement of your established fan base, whether it is trending up or down and how active and vocal that community is.  These are all a blend of objective and subjective measures but provide a far more accurate picture of social media success.

The empirical data presented by Hubspot is useful in that it provides a top-level sense of the interest in pharmaceutical social media engagement.  What it does not evaluate is how long the group has been established, what purpose it intends to serve, what benchmark for success has been determined and how active the group itself is.  These are all critical factors in evaluating success in pharma social media.

  • Share/Bookmark

View Comments »

Posted in Pharmaceutical Online Marketing, Pharmaceutical Social Media

Tags: Pharma on Facebook Pharmaceutical marketing Pharmaceutical Social Media

Who Owns Pharma Social Media? Who Cares?

June 15th, 2010 by Chris Iafolla View Comments »

Back in December, I wrote a post centered on the social media land grab.  This is what it boiled down to: agencies have recognized that social media presents an opportunity to add a revenue stream.  Of course, agencies always follow the money and suddenly everyone was looking to grab a piece of the proverbial pie.  It didn’t matter if you were a branding shop, a digital agency, an ad agency or a PR agency—everyone had a story as to why they were best suited for social media.

Unfortunately, that conversation has continued unabated seven months later.  Debate is running rampant on who owns social media.  But my question is: who cares?

The constant debate about who owns pharmaceutical social media is not only useless chatter; it’s detrimental to the industry.  While an ad guy is selling a campaign concept and a PR guy is selling the idea of building a reputation—the pharma marketer is left scratching their head.  We often counsel our clients on clarity and consistency of message yet we muddy the process for the very people we are trying to convince.  I may not have learned much in school but one thing I do know is that confusing the buyer is not a recommended selling tactic.

So to all my cohorts out there on the agency side, who are we trying to convince—ourselves or the prospect?

Instead of making a decision based on the type of agency you are considering, I would encourage pharma marketers to focus on a different set of criteria.  Ask questions that cover:

  • What is your process for setting strategy?
  • What is the most compelling reason for us to be involved in social media?
  • How will you handle a crisis communications situation online?
  • What is the goal of our engagement on social media?
  • How will you help me identify, create and extend the value of my content?
  • How will you identify the appropriate audiences for me to engage with?
  • How will you measure success during an engagement?
  • What departments do you plan on getting involved internally (i.e. legal, IT, etc.)?

These types of questions and many more will provide you with better insight on the right social media partner.  It might be a digital agency, or it might be an agency like mine.  But if the debate continually focuses on who owns social media—they are not right for the job.

  • Share/Bookmark

View Comments »

Posted in Pharmacetuical Public Relations, Pharmaceutical Online Marketing, Pharmaceutical Social Media

Tags: Pharmaceutical marketing Pharmaceutical Social Media PR for pharma

Social Media for Pharma Crisis Communications

June 4th, 2010 by Chris Iafolla View Comments »

Brief Programming Note: Apologies for the slow going on posting here as of late.  Between a work, real life and a vacation, it’s been difficult to carve out the time to write.  But alas, things look to be freeing up so I’ll be back at it more regularly.  I know; music to your ears.

Have you heard? A few pharmaceutical companies (and one oil company) have recently stepped into a healthy dose of crisis situations.  As is always the case, the response to those crises has been sliced, diced and pureed in every way imaginable.  The majority of industry pundits have been dissatisfied with the response of pharmaceutical companies in crisis situations and have pointed to their social media presence as proof of failed strategy.

I’m here to tell you it is not that simple.

In the midst of a crisis communications situation, there is a list 15 city blocks long of what a pharmaceutical company can’t say.  This is never more true than in the public eye of social media.  On the flip side, the list of things a pharma company can say when embroiled in a crisis is small enough to fit in your wallet.  So, all those calling for full transparency using social media are naïve.  I certainly would not suggest that a company should withhold pertinent information or intentionally deceive the public—but they simply cannot provide full transparency.  Why?  In many instances it’s illegal pending FDA review.  There is also a litany of legal considerations that put the squeeze on communications during a crisis. For example, no legal team at a pharmaceutical company would ever allow a public apology before all the facts have been sorted out.  In a legal sense, a public apology admits fault.  Fault implies responsibility and responsibility brings lawsuits.  It might seem callous, but that’s the reality.

Given the grim picture I have just painted, is there any hope for a pharmaceutical company dealing with a crisis.  Should they even be considering social media as a platform for handling a crisis and protecting their reputation?

While there is a long list of what you are not able to say during a crisis, you should be prepared to quickly say whatever is within bounds.  It sounds simple but too many companies get caught with their pants down under the assumption that a crisis won’t hit their companies.  A few well-respected brands would beg to differ.  You should enter a social media engagement expecting a crisis.  If you don’t expect a crisis then shame on you.  Knowing that a crisis situation may occur, you can then intelligently guess the areas where one is likely to arise.  Product recalls, disgruntled shareholders and adverse events seem likely to tip off a firestorm.  What are you doing to prepare for these circumstances?

Again, this is not about transparency for the sake of transparency.  A pharmaceutical company should not be taking to social media channels discussing specific adverse events.  But, it should be prepared to let the patient population know that they have been heard, the dialogue is open and they take the situation very seriously.  Pharmaceutical companies should also be prepared to offer additional resources.  Most pharmaceutical companies have case managers in their patient advocacy program—they should be at the ready during a crisis.  Top management should be visible and active.

There is a common misconception when it comes to crisis communications—that if done correctly, it is capable of solving the problem.  Regardless of how well you handle the crisis from a communications perspective, it still happened.  Crisis communications is not about fixing the problem, it’s about putting forward the human dynamic of a company—and there is no better way to do that than with social media.

  • Share/Bookmark

View Comments »

Posted in Pharmaceutical Crisis Communications, Pharmaceutical Online Marketing, Pharmaceutical Social Media

Tags: Pharmaceutical Crisis Communications Pharmaceutical Social Media Social media for pharma

Why Recent Pharma Social Media Stumbles Are a Good Thing

May 13th, 2010 by Chris Iafolla View Comments »

Johnson and Johnson saw patients take to social media after the McNeil Healthcare product recall.  Sanofi-aventis stood by as a group of angry patients first created a fake sanofi page to voice their concerns and then took to the official corporate page.  Even Astra-Zeneca took a social media beating when a vendor it was working with inadvertently left a database open for public viewing that contained insights  from a social media listening program.  This succession of missteps has caused many a marketer to panic thinking all of the progress on the pharma social media front will come to a grinding halt.

On the contrary, I think each of these situations is a good thing for pharmaceutical social media. Certainly, product recalls and disgruntled patients are never a positive, but the impact it had on social media will only stand to move efforts forward in the future.

I know what you are thinking: how could realizing every executive’s worst fear of social media aide progress?  Because it made it real.

If there was one thing that has most hindered social media efforts it was disillusionment.  Disillusionment on the part of pharma executives that thought it could reverse poor brand images.  Disillusionment on the part of social media advocates that mistakenly believed taking to social channels was the key to languishing marketing efforts.  And most importantly, disillusionment on the part of both pharmaceutical companies and agencies that thought social media occurred in a vacuum—insulated from the mistakes of other parts of the business.

Welcome to reality folks.  Social media is not a silver bullet.  It doesn’t exist in some alternate universe where your businesses problems do not reflect on your social media presence.  And for heaven’s sake, social media does not sweep problems under the rug—it rips the rug clean off the floor.

This recent string of social media challenges for pharmaceutical companies was a good thing.  It will weed out the folks that are selling social media as THE tool that will reverse the image of the pharmaceutical industry.  It will dispel the notion that social media is immune to crisis and that a comprehensive crisis communications plan isn’t needed.

These challenges will make us better.

  • Share/Bookmark

View Comments »

Posted in Pharmacetuical Public Relations, Pharmaceutical Crisis Communications, Pharmaceutical Social Media

Pharmaceutical Call Centers: A Path to Social Media Success

April 27th, 2010 by Chris Iafolla View Comments »

Much of the pharmaceutical social media conversation has focused on the need for change from the market tactics of yesteryear.  The argument goes something like this: “agree or disagree, the pharmaceutical industry is one of the most distrusted and its public perception is overwhelmingly negative.  Why?  Fair or unfair, many point the finger at the barrage of DTC ads as a sore point.”  Using that logic, the strategy tends to be something to the effect of “change everything.”

It’s not all wrong.  I for one have been a proponent of pharmaceutical social media as a step in the evolution of the industry’s marketing.  No doubt, the pharmaceutical marketing has been evolving over the years to fit better with a business less focused on blockbuster drugs and mass markets and more concerned with areas of high unmet needs and building relationships.  So by all means, move forward with radical changes to the way you form marketing strategy, but don’t disregard your past entirely—you might miss a crucial lesson.

Today, Wendy Blackburn from InTouch Solutions reposted an article that she authored (originally ran in Med Ad News) focused on how pharmaceutical companies can take a more customer-centric approach to marketing (similar to my Return on Health concept).  Within that post, Wendy briefly mentions an interesting point: “patient support call centers have been around a long time. What’s so difficult about duplicating that experience online? Why not empower a corporate spokesperson to speak online on behalf of your company and your brand?”

This is an example I’ve used on occasion before: if pharmaceutical companies can trust call center employees to handle patient support functions, why can’t they replicate that process for an online team?  There are really only two (honest) answers to this question.  The first is that online platforms expose the companies to added risk and exposure to the FDA.  The issues are the same as what might be handled in a call center but when dealt with in a public manner, the feeling is that companies are being watched.  Call centers don’t face that challenge.  Second is a problem of scale.  Call centers provide a finite and defined environment.  The company can control (to some extent) the calls it takes in a day, the hours it receives calls and the process for responding.  The real-time nature of the Web makes this level of control impossible.  That’s really about it: too much scrutiny and not enough resources.

Yet, people tend to ignore examples of the past even if they have worked.  Call centers have worked in the pharmaceutical industry for the most part.  So here is what it comes down to: do you trust your call center employees more than your communications manager?

  • Share/Bookmark

View Comments »

Posted in FDA and Pharma Social Media, Pharmaceutical Online Marketing, Pharmaceutical Social Media, Return on Health

Tags: FDA and Pharma Social Media Pharmaceutical Call Centers Pharmaceutical marketing Pharmaceutical Social Media

Notice to Pharmaceutical Marketers: Facebook and Twitter are Not Social Media

April 26th, 2010 by Chris Iafolla View Comments »

I’ve said this a few times before; but I think it’s worth repeating based on a number of conversations I’ve recently had with pharmaceutical marketers.  Here it goes: Facebook, Twitter and blogs are not social media. I repeat, just because you throw up a Facebook page does not mean you have a social media presence.

A Facebook page without interaction is nothing more than a Website.  A Twitter handle without engagement equates to an RSS Feed and a blog without open commentary may as well be a company newsletter.  The point?  Social comes first in social media for a reason. Far too many pharmaceutical companies focus on the latter and ignore the former.  The results can be disastrous in an age when executives are demanding quantifiable ROI and quick results.

The most value that healthcare companies can be derived from social media stems from connecting directly with customers (in the case of pharmaceutical companies: patients, doctors, healthcare providers, insurance providers, etc…).  This is where you will hear invaluable feedback on your product or brand, come to intimately understand the decision-making process for requesting a certain prescription, learn the types of information most valuable to the patient and earn the type of trust that creates loyal brand advocates.  Anything short of that is marketing as usual.

Sure, there are some additional benefits to establishing a presence on social media channels that can be achieved without being truly social such as search engine juice.  If you churn out enough content focused on the term “cancer research” you will probably rank higher in search results.  But what about all the other content organizations are churning out on the same topic?  Are you present in those conversations?  If not, you are missing an opportunity to extend your social media presence, provide simplified access to information and establish a new relationship with your company.  There are important touchpoints outside of your own social media presence that should not be ignored.

As a social media marketer, focusing on the tools perpetuates the myth that this is just a fad and purely tactical in nature.  Fads do not get a sizable portion of the marketing budget and tend to fizzle out in due time.  My advice: stop focusing on the “media” and start worrying about the social.

  • Share/Bookmark

View Comments »

Posted in Pharmaceutical Online Marketing, Pharmaceutical Social Media

Tags: Facebook for Pharmaceutical Companies Pharmaceutical marketing Pharmaceutical Social Media Twitter for Pharmaceutical Companies

« Older Entries
    • Subscribe Subscribe to my blogs feed
  • Where I Work:
    • logo
  • Tweet Blender
    Twitter Logo
    Refresh
    FxpowersFxpowers: RT @roskadigital: 'Most Brands Still Irrelevant on Twitter' - Great info on the platform: http://ow.ly/2he8f #hcsm #socpharm #hcmktg
    5 hours ago from HootSuite
    reply | follow Fxpowers
    PRforPharmaPRforPharma: RT @SHIFTcomm: Yowsa. RT @RichBecker: Best Fresh Content Pick: Social Media Spend to Double This Year http://bit.ly/95PVae by @briansolis
    5 hours ago from Seesmic
    reply | follow PRforPharma
    MatthewBrowningMatthewBrowning: RT @kevinkruse: July Early-bird rate for e-Patient Connections (epatient2010.com) ends TODAY. #ePatCon #hcsm #fdasm #hcsmeu #health2 #h2con
    5 hours ago from TweetDeck
    reply | follow MatthewBrowning
    blueeyepathblueeyepath: In case u missed this one: How One Pharma Company Successfully Manages YouTube - http://pbeye.info/3WK (via @jonmrich) #socpharm #hcsm
    5 hours ago from web
    reply | follow blueeyepath
  • Powered by Postrank
  • What you are saying
    • Salud con cosas: Realismo semanal: nuestro resumen on Content Creation: Where Pharma Social Media Goes to Die
    • Tweets that mention Content Creation: Where Pharma Social Media Goes to Die | PRforPharma -- Topsy.com on Content Creation: Where Pharma Social Media Goes to Die
    • Chris Iafolla on Failing to Empower the Empowered Patient
    • Alicia C. Staley on Failing to Empower the Empowered Patient
    • Tweets that mention Pharma Social Media Failing to Empower the Empowered Patient | PRforPharma -- Topsy.com on Failing to Empower the Empowered Patient
  • Pharma Reading
    • Bradatpharma
    • Dose of Digital
    • ePharmaRx
    • Eye on the FDA
    • Impactiviti Blog
    • Med 2.0
    • MedAdNews Insider
    • Pharma Analysis
    • Pharma Marketing Blog
    • Pharma Strategy Blog
    • Pharmalot
    • The Healthcare Blog
    • Wall Street Journal Health Blog
    • Whydotpharma
    • World of DTC Marketing
  • PR/Marketing Reading
    • 6 a.m
    • A Shel of my Former Self
    • Bryan Person
    • Communication Overtones
    • Doug Haslam
    • Marketing Roadmaps
    • Now is Gone
    • Personal Branding Blog
    • POP PR Jots!
    • PR 2.0
    • PR-Squared
    • The Buzz Bin
  •  
    July 2010
    M T W T F S S
    « Jun    
     1234
    567891011
    12131415161718
    19202122232425
    262728293031  

Back to Top

© 2010 PRforPharma · Proudly powered by WordPress & Green Park 2 by Cordobo.

Valid XHTML 1.0 Transitional | Valid CSS 3

Cordobo Green Park 2 logo